Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020.
Fitzgerald Pharmaceutical Industries
Selected Balance Sheet Information
June 30, 2020
|
Long-term debt |
|
00Notes payable, 10% |
$ 1,000,000
|
008% convertible bonds payable |
5,000,000
|
0010% bonds payable |
6,000,000
|
0000Total long-term debt |
$12,000,000
|
Shareholders' equity |
|
00Preferred stock, 6% cumulative, $50 par value,
100,000 shares authorized, 25,000 shares issued
and outstanding |
$ 1,250,000
|
00Common stock, $1 par, 10,000,000 shares authorized,
1,000,000 shares issued and outstanding |
1,000,000
|
00Additional paid-in capital |
4,000,000
|
00Retained earnings |
6,000,000
|
0000Total shareholders' equity |
$12,250,000
|
|
|
The following transactions have also occurred at Fitzgerald.
1. Options were granted on July 1, 2019, to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share.
2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019.
3. The preferred stock was issued in 2019.
4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020.
5. The 1,000,000 shares of common stock were outstanding for the entire 2020 fiscal year.
6. Net income for fiscal year 2020 was $1,500,000, and the average income tax rate is 20%.
Instructions
For the fiscal year ended June 30, 2020, calculate the following for Fitzgerald Pharmaceutical Industries.
a. Basic earnings per share.
b. Diluted earnings per share.